Aethlon Medical, Inc. · NASDAQ (us_market)
Healthcare · Medical Devices · United States
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-23$3.28 RISE2026-05-18$2.04 PEAK2026-05-27$3.07 124d | -37.8% 115d | Missed | Missed | — | — | +50.5% 9d | Missed |
DROP2025-10-29$5.75 RISE2026-03-11$1.65 PEAK2026-05-27$3.07 210d | -71.3% 133d | Missed | Missed | — | — | +86.1% 77d | Missed |
DROP2025-05-20$32.80 RISE2025-09-10$6.50 PEAK2025-10-02$8.00 135d | -80.2% 113d | Missed | Missed | — | — | +23.1% 22d | Missed |
DROP2025-05-20$32.80 RISE2025-09-09$6.50 PEAK2025-10-02$8.00 135d | -80.2% 112d | Missed | Missed | — | — | +23.1% 23d | Missed |
DROP2025-03-05$39.20 RISE2025-07-14$11.50 PEAK2025-08-21$21.90 169d | -70.7% 131d | Missed | Missed | — | — | +90.4% 38d | Missed |
DROP2025-01-06$72.80 RISE2025-04-21$26.40 PEAK2025-04-29$32.80 113d | -63.7% 105d | Missed | Missed | — | — | +24.2% 8d | Missed |
DROP2024-08-23$48.00 RISE2024-12-16$28.00 PEAK2025-01-06$72.80 136d | -41.7% 115d | Missed | Missed | — | — | +160.0% 21d | Missed |
DROP2024-06-18$54.40 RISE2024-10-24$29.60 PEAK2025-01-06$72.80 202d | -45.6% 128d | Missed | Missed | — | — | +145.9% 74d | Missed |
DROP2024-04-02$140.80 RISE2024-08-05$20.80 PEAK2024-08-23$48.00 143d | -85.2% 125d | Missed | Missed | — | — | +130.8% 18d | Missed |
DROP2024-01-23$156.00 RISE2024-05-30$32.00 PEAK2024-06-13$55.20 142d | -79.5% 128d | Missed | Missed | — | — | +72.5% 14d | Missed |
DROP2024-01-09$160.80 RISE2024-05-17$32.00 PEAK2024-06-13$55.20 156d | -80.1% 129d | Missed | Missed | — | — | +72.5% 27d | Missed |
DROP2024-01-08$163.20 RISE2024-05-16$32.00 PEAK2024-06-13$55.20 157d | -80.4% 129d | Missed | Missed | — | — | +72.5% 28d | Missed |
DROP2024-01-05$168.00 RISE2024-05-15$32.00 PEAK2024-06-13$55.20 160d | -81.0% 131d | Missed | Missed | — | — | +72.5% 29d | Missed |
DROP2023-07-12$360.00 RISE2023-10-18$113.60 PEAK2023-12-29$175.20 170d | -68.4% 98d | Missed | Missed | — | — | +54.2% 72d | Missed |
DROP2023-02-01$560.00 RISE2023-05-31$240.00 PEAK2023-07-12$360.00 161d | -57.1% 119d | Missed | Missed | — | — | +50.0% 42d | Missed |
1–15 / 36 1 / 3 | |||||||
No scored news yet for a sentiment trend.
Which stocks have an unusual volume on Thursday?
Phreesia (NYSE: PHR) shares rose in pre-market trading after better-than-expected sales results. Other gainers include Snowflake, Genius Group, and Astrotech.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is actively monitoring developments
By M. Marin NASDAQ: AEMD READ THE FULL AEMD RESEARCH REPORT DSMB recommends AEMD progress clinical trial to the final third cohort Aethlon Medical (NASDAQ: AEMD) announced today that the independent Data Safety Monitoring Board (DSMB) overseeing the clinical trial it is conducting to assess lead asset, the Aethlon Hemopurifier, as a potential treatment in oncology, has completed its safety review
Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were
Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that
NASDAQ: AEMD Lili Elston: Hello, and welcome to the Life Sciences Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we are very pleased you've joined us. The next presentation of the day is from Aethlon Medical . Their session will be moderated by M. Marin, Senior Analyst with Zacks Small Cap Research . Please note, you may submit questions for the presenter.
By M. Marin NASDAQ: AEMD READ THE FULL AEMD RESEARCH REPORT Company’s current strategic focus is assessing the Hemopurifier in oncology… We participated in a chat with Aethlon Medical (NASDAQ: AEMD) CEO and CFO Jim Frakes last week and present our key takeaways in this report. The company’s lead asset, the Aethlon Hemopurifier, is an investigational extracorporeal device designed to bind and
SAN DIEGO, CA - March 13, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released the following shareholder update au...
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging tec
Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process.
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the on
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that Jim Frakes, CEO and CFO, will
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AEMD | -3.91% | +18.18% | -20.22% | -92.53% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.88% | +23.90% | -16.77% | -105.22% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-06-24upcoming | -2.45 | — | — |
| 2026-02-12 | -2.01 | -2.45 | -21.89% |
| 2025-11-12 | -3.66 | -3.74 | -2.09% |
| 2025-08-13 | -7.30 | -8.50 | -16.44% |
| 2025-06-26 | -10.90 | -37.00 | -239.45% |
| 2025-02-12 | -16.27 | -10.40 | +36.07% |
| 2024-11-13 | -15.60 | -16.00 | -2.56% |
| 2024-08-14 | -25.20 | -27.20 | -7.94% |
| 2024-06-27 | -98.40 | -72.80 | +26.02% |
| 2024-02-14 | -109.33 | -109.60 | -0.24% |
| 2023-11-14 | -112.00 | -97.60 | +12.86% |
| 2023-08-10 | -104.00 | -112.00 | -7.69% |
| 2023-06-28 | -116.00 | -88.00 | +24.14% |
| 2023-02-13 | -140.00 | -96.00 | +31.43% |
| 2022-11-14 | -172.00 | -144.00 | +16.28% |
| 2022-08-09 | -176.00 | -152.00 | +13.64% |